Abstract: Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an ?-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.

Abstract: This invention relates to a novel soy isoflavone product with high purities and strong biological activities and the method of producing the same from natural soybeans, soybean materials (i.e. tofu dregs, soy molasses) and other plant sources. The method includes three steps consisting of extraction with an organic solvent, hydrolysis using an acid and crystallization using an antisolvent. The procedure is very simple and thus can be easily adapted for large-scale manufacturing. Moreover, the procedure is able to produce a high yield of total isoflavones at a lower cost. HPLC analysis and E-Screen bioassay reveal that the obtained product not only contains a high content of isoflavone aglycones by weight of dry matter but also exhibits strong estrogenic activity toward human cells. Therefore, the product should be efficacious for relieving menopausal symptoms and other estrogen-deficient diseases and can be used in health care supplements or as additives for foods, beverages or cosmetics.

Abstract: The invention relates to a composition and a method for mitigating redness or inflammation of mammalian skin comprising administering to mammalian skin a composition consisting of an effective amount of alkanolamine, feverfew or soy or mixtures thereof, one or more optional benefit agents and one or more cosmetically acceptable carriers. More particularly, it relates to a composition for mitigating skin irritations such as retinol/retinoid irritation and their applications to mammalian skin.

Abstract: Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

Abstract: The present invention relates to specific synergistic active skin- and/or hair-lightening and/or senile keratosis-reducing (cosmetic or pharmaceutical) preparations comprising a mixture comprising or consisting of a) a tyrosinase-inhibiting amount of one or more compounds of the formula 1: ?wherein: R1 is hydrogen, methyl, straight-chain or branched alkyl having 2-4 C atoms, OH or halogen, R2 is hydrogen, methyl or straight-chain or branched alkyl having 2-5 C atoms, R3 is methyl or straight-chain or branched alkyl having 2-5 C atoms, and R4 and R5 are, independently of one another hydrogen, methyl, straight-chain or branched alkyl having 2-5 C atoms, OH or halogen and b) a skin- and/or hair lightening and/or senile keratosis-reducing amount of one or more compounds selected from the group consisting of (i) chelating agents, (ii) phenolic derivatives, plant extracts with an amount of phenolic derivatives and (iii) organic acid derivatives as well as uses thereof.

Abstract: The invention is related to methods and compositions for increasing milk production in animals using a saponin containing composition. In an embodiment, the invention is a method for increasing milk production of an animal comprising administering an initiation dose of a saponin-containing composition to the animal within five days before or after the time of freshening of the animal, and administering a plurality of maintenance doses of the saponin-containing composition to the animal.

Abstract: Compositions and methods for reducing hypercholesterolemia and, accordingly, the risk of cardiovascular disease, are provided. Such compositions may comprise isolated oil body associated proteins. Additionally provided are foodstuffs to which one or more oil body associated proteins have been added. The compositions employed in the invention may further comprise additive compounds, for example, a saponin, an isoflavone, a phospholipid, a carbohydrate substantially resistant to digestion, or a combination thereof. The methods and compositions of the invention may be used to lower cholesterol and other lipid levels in subjects to achieve a reduction in the risk of cardiovascular disease.

Abstract: A device for administering aromatherapy to a subject and the method of using the device are disclosed. The device comprises an aromatherapy composition housed within a container. The container has at least one opening or aperture through which the subject may breathe in or inhale the aromatic and volatile components of the aromatherapy composition through the mouth and/or nose. The aromatherapy composition comprises a particulate component comprising one or more irregularly- or regularly-shaped particles, granules, beads or the like. In addition, the aromatherapy composition has a volatile component comprising an amount of an essential oil-containing composition. The volatile component is that portion of the essential oil-containing composition that is retained by the particulate component after contacting the particulate component with the essential oil-containing composition and removal of the portion that is not retained by the particulate component.

Abstract: An herbal composition that provides anti-cancer effects, especially for breast cancer.

Abstract: The aim of this invention is to offer a novel agent for hair growth, which has excellent hair growth effects but not side effects. The agent for hair growth of the present invention is characterized by comprising a processed semi-mature soybean and/or a processed semi-mature soybean extracts and at least one substance selected from the group consisting of a processed Polygoni Multiflori Radix, processed Polygoni Multiflori Radix extracts, a processed Cynanchum bungei Decne or processed Cynanchum bungei Decne extracts, preferably further comprising Longan seed and/or Longan seed extracts as active ingredients. This agent for hair growth has no side effects when used externally or internally, it can notably improve hair growth within a short period of time; ranging from 6 to 12 weeks, can return hair to its normal hair colour (for example from white to black) and can improve the gloss of hair.

Abstract: emollient and methyl salicylate, where said methyl salicylate comprises between 10 and 30 percent by weight of said cream; a skin stimulant comprising menthol crystals and two or more reactants selected from a group of camphor, cinnamomum cassia, diclofenac, eucalyptus, and ginger to cause a hot and cool stimulus on an epidermal surface; a pain reliever comprising two or more agents selected from a group of benzocaine, emu oil, eucalyptus oil, methylsulfonylmethane and glucosamine; and an inflammatory comprising two or more agents selected from a group of artemisia vulgaris, amica Montana flower extract, licorice root extract, oat extract, and thyme oil.

Abstract: Dicot, and especially Brassicaceae sprout preparations are employed as a dietary agents that significantly reduce oxidized species in human serum. In one especially preferred aspect, contemplated compositions are employed to reduce serum oxLDL and to increase serum HDL levels.

Abstract: The invention relates to medicine, in particular to pharmacology, and is embodied in the form of an agent for limiting neuro-mediator, neuro-endocrine and metabolic disturbances generating the disorders of a central nervous system and functional somatic disorders. The inventive agent is based on a DSIP (delta sleep inducing peptide) or a derivative chemically related thereto and can be used for correcting and preventing functional shifts in a central nervous system and concomitant somatic disorders caused by unfavourable and extreme environmental factors and different pathological conditions of an organism or during the ageing thereof.

Abstract: The present invention relates to a method for treating diabetic complications, which comprises administering an extract obtained by: crashing and drying any one selected from Euphorbiae radix, gingered Magnolia bark, parched Puerariae radix and Glycyrrhizae radix; extracting the dried herbal material with alcohol or aqueous alcohol solution; filtering the extract; and concentrating the filtrate under reduced pressure.

Abstract: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

Abstract: A method of producing an enriched flavonoid aglycone extract from starting material containing a suitable flavonoid glycoside and/or conjugate thereof comprising the steps of: (i) enzymatically converting the flavonoid glycoside or conjugate thereof into the flavonoid aglycone; (ii) adjusting the pH to render the flavonoid aglycone soluble and removing the insoluble fraction; and (iii) adjusting the pH to render the soluble flavonoid aglycone relatively insoluble and forming an extract containing the same.

Abstract: The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in hydrolyzed soy protein derived materials. The invention further relates to the use of these T2R receptors in assays for identifying ligands that modulate the activation of these taste receptors by specific bitter ligands present in hydrolyzed soy protein materials and derivatives thereof and related compounds. These compounds may be used as additives and/or removed from soy-based foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste elicited by bitter ligands present in hydrolyzed soy protein materials.

Abstract: The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic uses; (v) a composition for industrial applications comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

Abstract: Estrogenic extracts of Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Abstract: Extracts of various species of the Leguminosae family have estrogenic properties. For example, aqueous and ethanolic extracts of Pueraria lobata Willd. Ohwi of the Leguminosae family species possess estrogenic properties in both ER?+ and ER?+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and/or uterine cancer, and osteoporosis.

Abstract: By heating a solution or paste containing soybean ?-conglycinin protein under acidic conditions, it is possible to provide soybean ?-conglycinin protein whose high hydration property and high viscosity, which are problematic in various food processing using it or at the time of ingestion thereof, are improved.

Abstract: The invention concerns the treatment of obesity, in particular abdominal visceral obesity. More specifically, the invention concerns the use of selective 15-lipoxygenase (LO) inhibitors for preparing medicines useful in the treatment of obesity, or at least abdominal visceral obesity, and/or its consequences.

Abstract: A cosmetic material, cell growth promoting agent, elastase activity inhibiting agent and anti-aging agent containing sweet pea extract, formulated with the aim of preventing or slowing aging.

Abstract: Composition for topical treatment of various forms of acne including (a) 20-40% by volume of an extract of a GLYCYRRHIZA GLABA plant; (b) 15-30% by volume of an extract of a FOENICULUM OFFICINALE plant; (c) 15-45% by volume of a saturated water solution of at least one mineral salt selected from the group of NaCl,r KCl and MgCl2; and (d) 1-3% by volume of an extract of a ATRIPLEX HALIMUS plant.

Abstract: Compositions and methods of use of annatto extracts [350-450 Dalton molecular weight fraction] including tocotrienols and tocopherols with an appropriate spectrum. This spectrum includes but not limited to low alpha tocopherol, high delta- and gamma-tocols, and mixtures with other extracts [350-450 Dalton molecular weight fraction] like palm and rice and/or nutrients.

Abstract: The present invention relates to an oil/fat-containing composition for suppressing carcinogenesis, the composition including a solution produced by bringing a hydrophobic extract of licorice, which has been produced by bringing licorice into contact with an alcohol, into contact with an oil/fat. According to the present invention, there are provided an oil/fat-containing composition for prevention or treatment of the cancer, which can act through oral administration, and can be safely ingested on a day-to-day basis, pharmaceuticals and foods containing the oil/fat-containing composition.

Abstract: Heat-stabilized defatted rice bran (HDRB) is fermented with yeast to afford a food product having superior prebiotic for probiotic properties. Fermentation of HDRB with yeast yields a prebiotic composition that can promote the growth and/or activity of beneficial intestinal bacteria (probiotic) when consumed by an animal or human. The prebiotic and/or probiotic compositions can afford substances having desirable health effects when consumed. The yeast fermented, and the probiotic fermented extracts and residues will have several nutraceutical compounds including protein, phenolics, phytic acid, arabinose, bioactive isoflavones, dietary fibers and several others that will have health benefits. Inclusion of legumes during fermentation can synergistically enhance the bioactivities of HDRB. HDRB can be a source of growth medium for yeast/mold/microorganisms.

Abstract: A combination comprising verbascoside and luteolin, and its use in a cosmetic or pharmaceutical composition for pigmentation modulation.

Abstract: The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components.

Abstract: The present invention relates mainly to a cosmetic process for making up and/or caring for keratin material(s), comprising the application, on contact with a keratin material, of at least one cosmetic composition comprising at least 75% by weight, relative to its total weight, of compound(s) approved for food use and having a gloss value at least greater than or equal to about 5.

Abstract: The present invention provides multi-step methods for treating pain and/or inflammation. In a preferred embodiment, the method comprises administering to a patient in need of relief of pain and/or inflammation the following three components: (1) a skin penetration enhancer; (2) a daytime analgesic; and (3) a nighttime joint and muscle rejuvenator. The present invention also provides an analgesic composition comprising PHYTOLANE LS® and garlic oil, preferably in a cream or ointment base.

Abstract: The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin cosmetic applications.

Abstract: A protein body derivable from Fabaceae has a reversible, anisotropic contractability such that the protein body becomes thicker perpendicular to a longitudinal axis of the protein body and shorter along the longitudinal axis of the protein body when increasing a calcium ion concentration in a medium surrounding the protein body past a threshold value of 30 nM. The protein body becomes thinner perpendicular to the longitudinal axis and longer along the longitudinal axis when decreasing the calcium ion concentration below the threshold value of 30 nM. Also, the protein body becomes thicker in the direction perpendicular to the longitudinal axis when increasing a pH value of a medium surrounding the protein body to a value above 9.5 without becoming shorter along the longitudinal axis. The protein body becomes thinner in the direction perpendicular to the longitudinal axis without becoming longer decreasing the pH value below 9.5.

Abstract: A method of inhibiting COX-2, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Campsiandra angustifolia to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Campsiandra angustifolia suspended in the vehicle. A method of making an extract of Campsiandra angustifolia may comprise creating a component solution by treating Campsiandra angustifolia material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Campsiandra angustifolia may comprise components extracted using various solvents.

Abstract: The present invention provides a powder superior in water-dispersibility/solubility, workability and tabletability, which contains an oil component containing a bioactive substance, a water-soluble polymer, a saccharide other than polysaccharides and a surfactant, at a particular ratio. The powder can be utilized for food, food with nutrient function claims, food for specified health uses, nutritional supplement, nutritional product, animal drug, drinks, feed, pharmaceutical product, quasi-drug, cosmetic and the like.

Abstract: The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases.

Abstract: A chicken feed composition to promote health or rejuvenate egg production comprising pecan byproduct meal, and a method of feeding chickens to promote health or rejuvenate egg production using the feed composition. Addition of pecan byproduct meal to the feed effectively reduces calorie consumption, body weight, and egg production as desired for the rejuvenation of laying chickens, without resorting to the objectionable practice of extended feed withdrawal. Further, addition of pecan byproduct meal to the feed may positively affect the health of hens in the same manner as conventional fibrous feedstuffs.

Abstract: Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and/or degenerative diseases, disorders, conditions, and processes in humans and other animals.

Abstract: Preservative compositions containing emollient solvents such as octanediol or Symdiol™ or octoxyglycerine monoesters in combination with organic acids such as alpha hydroxyl acids can be used for preventing microbial growth and spoilage in cosmetic and topical skin formulations with the added benefit of providing silky smooth texture to skin. The compositions may optionally contain an essential oil/component. These preservative compositions are odorless and colorless and small concentrations can be added to cosmetic/topical formulations to prevent bacterial, yeast and fungal growth within 24 to 48 hours after contamination.

Abstract: A process for the extraction, purification and enzymatic modification of ?-conglycinin ?? subunit, wherein ?-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the ?? subunit, which is treated with chymotrypsin, then subjected to a further MAC to recover the amino-terminal region of this polypeptide (MW 28,000 Da).

Abstract: A process for releasing and extracting phosphatides from a phosphatide-containing matrix. The process includes (i) contacting the phosphatide-containing matrix with a solvent and a metal salt to release phosphatides from the matrix and form a phosphatide enriched solvent portion and a phosphatide depleted matrix portion, (ii) separating the phosphatide enriched solvent portion from the phosphatide depleted matrix portion, and (iii) recovering the phosphatides from the phosphatide enriched solvent portion.

Abstract: A drinking water for a diabetic including water of 93˜97 wt %; budded Oryza sativa of 2.5˜5 wt %; Zingiber officinale of 0.04˜0.07 wt %; and Glycyrrhiza uralensis of 0.01-0.05 wt %.

Abstract: A method of lowering blood cholesterol in a non-diabetic human patient by at least 30% is described. The method involves orally administering for 30 consecutive days a fenugreek seed extract composition. Various methods of preparation and various formulations are described. Agents such as pharmaceutically acceptable excipients, lubricants, binders, glidants, fillers, flavoring agents, vitamins, minerals, active agents other than fenugreek, herbal extracts other than fenugreek, carriers and mixtures thereof may be additionally incorporated into the fenugreek seed extract composition. Physiologically effective dosage forms (liquid and solid) containing fenugreek seed extract compositions are also disclosed.

Abstract: This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate and/or oxaloacetate, fruit extracts and anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains substances that should attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O2.

Abstract: The invention relates to compositions and methods for the treatment of intestinal pathologies. The invention also relates to compositions and methods which can be used to regulate the paracellular permeability of the intestinal epithelium. The inventive compositions and methods are based in particular on the use of protease inhibitors which modulate the opening of the tight junctions of the intestinal epithelium. The invention can be used for preventive or curative treatment of different pathologies, such as functional digestive disorders (FGID), in particular intestinal functional disorders (IFD) causing hyperalgesia and in particular irritable bowel syndrome (IBS), in mammals, particularly humans.

Abstract: A composition containing a licorice polyphenol and other active ingredient (antioxidant ingredient, polyphenol other than licorice polyphenol or a component relating to lipid absorption or metabolism) is highly safe, can be produced easily, and can be utilized for foods and drinks such as health food, food with health claims (specified health food, food with nutrient function claims) and the like, pharmaceutical products, quasi-drugs, cosmetics and the like. In addition, since the composition has a body fat accumulation suppressing effect, a body fat decomposition promoting effect or energy production promoting effect, it is useful for the treatment of obesity, metabolic syndrome and the like.

Abstract: The present invention provides a body fat-reducing agent containing a processed pueraria flower as an active component. The body fat-reducing agent has a superior body fat-reducing effect. Furthermore, the body fat-reducing agent may contain at least one of a lipid absorption suppressing component and a lipid metabolism promoting component. A food product, which contains the body fat-reducing agent, provided according to the present invention has superior effects of preventing body fat accumulation and reducing body fat.

Abstract: A method for prevention or therapy of pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria by administration of two kinds of crude drugs—seeds of Cucurbita moschata and flowers of Carthamus tinctorius—and at least one crude drug selected from Plantago asiatica, Lonicera japonica, Glycyrrhiza uralensis, Coix lachrymal-jobi var. ma-yuen, Zingiber officinale, Curcuma longa, Curcuma zedoaria and Artemisia argyi to a patient; and a health food for prevention, or improvement, or reduction of these symptoms containing the above substances.

Abstract: A gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles is described.

Abstract: An ingestible formulation for a plaque eliminator for animals that works systemically and comprises a formulation of a chlorophyll or a chlorophyll derivative combined with Spirulina and alfalfa wherein the chlorophyll derivative is at least 90 percent of the formulation is presented. In the preferred embodiment, the chlorophyll derivative is chlorophyllin. The formulation may be a capsule, liquid, tablet, or gelcap when in its usable form with the preferred embodiment being in a capsule formulation. When produced in tablet form, the formulation may also include a tableting agent. The formulation has a dissolution time generally sufficient to allow the formulation to pass an animal's stomach before beginning to breakdown. The formulation is dose dependent and will vary depending on the size of the animal to which it is given.